Comment on

• Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.

  Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M. Demoulin N, et al. Am J Kidney Dis. 2022 May;79(5):717-727. doi: 10.1053/j.ajkd.2021.07.018. Epub 2021 Sep 9. Am J Kidney Dis. 2022. PMID: 34508834 Review.
• Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease.

  Dejban P, Wilson EM, Jayachandran M, Herrera Hernandez LP, Haskic Z, Wellik LE, Sinha S, Rule AD, Denic A, Koo K, Potretzke AM, Lieske JC. Dejban P, et al. Clin J Am Soc Nephrol. 2022 Mar;17(3):414-422. doi: 10.2215/CJN.11730921. Epub 2022 Jan 25. Clin J Am Soc Nephrol. 2022. PMID: 35078782 Free PMC article.
• New therapeutics for primary hyperoxaluria type 1.

  Dejban P, Lieske JC. Dejban P, et al. Curr Opin Nephrol Hypertens. 2022 Jul 1;31(4):344-350. doi: 10.1097/MNH.0000000000000790. Epub 2022 Mar 9. Curr Opin Nephrol Hypertens. 2022. PMID: 35266883 Free PMC article. Review.
• PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.

  Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators. Baum MA, et al. Kidney Int. 2023 Jan;103(1):207-217. doi: 10.1016/j.kint.2022.07.025. Epub 2022 Aug 22. Kidney Int. 2023. PMID: 36007597 Clinical Trial.